[Intravenous human immunoglobulin treatment for neonatal alloimmune thrombocytopenia due to anti-HPA-5b with severe previous history].
Fetal and neonatal alloimmune thrombocytopenia due to mothers' anti-HPA-5b alloimmunization has generally a milder clinical presentation compared to anti-HPA-1a alloimmunization. Nevertheless, a case with infant's death probably due to intracranial haemorrhage has been reported. However, if platelet-specific alloimmunized mothers with prior fetal or neonate injury receive intravenous immunoglobulins during pregnancy, thrombocytopenia in heterozygous fetus and neonate may be prevented. Here are reported 2 cases of anti-HPA-5b fetal-maternal alloimmunization, one with prior fetal death, the other with prior severe fetal intracranial haemorrhage, which were successfully treated with intraveinous immunoglobulins alone during a second pregnancy with HPA-5b incompatibility.
Moncharmont
P
P
Etablissement français du sang, Rhône-Alpes, site de Lyon-Gerland, 1-3, rue du Vercors, 69364 Lyon cedex 07, France. pierre.moncharmont@efs.sante.fr
Vignal
M
M
Merieux
Y
Y
Rigal
D
D
D000328:Adult; D016824:Antigens, Human Platelet; D001792:Blood Platelets / Q000276:immunology*; D005260:Female; D005315:Fetal Diseases / Q000276:immunology / Q000628:therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000276:immunology / Q000628:therapy*; D008297:Male; D008431:Maternal-Fetal Exchange / Q000276:immunology; D011247:Pregnancy; D013921:Thrombocytopenia / Q000276:immunology / Q000628:therapy
C055973:5b alloantigen, human; D016824:Antigens, Human Platelet; D016756:Immunoglobulins, Intravenous